FDA Tells Celera KIF6 Test Unapprovable Without Changes
April 21, 2011
FDA Tells Celera KIF6 Test Unapprovable Without Changes
In a letter to the company, FDA told Celera that it may have to collect additional data on clinical utility to demonstrate the safety and effectiveness of its KIF6 Genotyping Assay.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Future of Celera's KIF6 Test Unclear Amid FDA Rejection, Pending Quest Acquisition
April 27, 2011 / Pharmacogenomics Reporter - Epigenomics' FDA Application for Cancer Test to Get FDA Priority Review
February 21, 2013 / GenomeWeb Daily News - Affymetrix Files for FDA Clearance of CytoScan HD
February 15, 2013 / GenomeWeb Daily News - Qiagen Submits EGFR Companion Dx to FDA
January 15, 2013 / GenomeWeb Daily News - Exact Sciences Submits First Module of PMA for Cologuard MDx Colorectal Cancer Screen to FDA
December 11, 2012 / GenomeWeb Daily News